← Back to Search

Probiotic

VRx MyBiotics Lozenges for Oral Microbiome Health

N/A
Waitlist Available
Led By Momchilo Vuyisich
Research Sponsored by Viome
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up ~ 4 months
Awards & highlights

Study Summary

This trial will test if a lozenge can improve oral health by changing the bacteria in the mouth.

Who is the study for?
This trial is for English-speaking adults in the US with at least 20 natural teeth, who can follow instructions and consent to participate. It's not for pregnant individuals, those on recent antibiotics or with major oral diseases, cancer patients, or anyone planning significant diet/lifestyle changes.Check my eligibility
What is being tested?
The study examines if VRx MyBiotics Oral Lozenges can improve oral microbiome health. Participants will use these lozenges and their effects on the mouth's microbial community will be assessed.See study design
What are the potential side effects?
Potential side effects are not detailed but may include reactions to ingredients like tapioca, peppermint, or sweet potato which are present in the lozenges.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~~ 4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and ~ 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Viome Oral Health Score

Trial Design

1Treatment groups
Experimental Treatment
Group I: VRx MyBiotics Oral LozengesExperimental Treatment1 Intervention
Participants will receive a 30 day supply of their personalized oral biotic lozenges.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VRx MyBiotics Oral Lozenges
2023
N/A
~40

Find a Location

Who is running the clinical trial?

ViomeLead Sponsor
20 Previous Clinical Trials
37,503 Total Patients Enrolled
Momchilo VuyisichPrincipal InvestigatorViome
11 Previous Clinical Trials
2,728 Total Patients Enrolled

Media Library

VRx MyBiotics Oral Lozenges (Probiotic) Clinical Trial Eligibility Overview. Trial Name: NCT05972330 — N/A
Oral Microbiome Health Research Study Groups: VRx MyBiotics Oral Lozenges
Oral Microbiome Health Clinical Trial 2023: VRx MyBiotics Oral Lozenges Highlights & Side Effects. Trial Name: NCT05972330 — N/A
VRx MyBiotics Oral Lozenges (Probiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05972330 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants welcomed into this research endeavor?

"Yes, recent updates to clinicaltrials.gov confirm that recruitment for this trial is ongoing. The study was first posted on June 26th 2023 and has since been updated as recently as July 24th 2023 with the aim of enrolling 31 patients at a single medical centre."

Answered by AI

How many individuals are being included in this medical experiment?

"Indeed, according to the clinicaltrials.gov website this experiment is actively seeking participants. Its initial post was made on June 26th 2023 and it has been most recently updated on July 24th of the same year. The trial requires 31 individuals from a single site."

Answered by AI

Who else is applying?

What site did they apply to?
Viome Life Sciences
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Efficacy of VRx MyBiotics Oral Lozenges
2023. "Efficacy of VRx MyBiotics Oral Lozenges". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05972330.
~19 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top